LATAGLIATA, Angelo Raffaele
 Distribuzione geografica
Continente #
NA - Nord America 381
EU - Europa 141
AS - Asia 106
AF - Africa 4
SA - Sud America 2
Totale 634
Nazione #
US - Stati Uniti d'America 376
SG - Singapore 65
IT - Italia 64
SE - Svezia 34
IN - India 25
CN - Cina 13
BG - Bulgaria 9
DE - Germania 8
CA - Canada 5
GB - Regno Unito 5
RO - Romania 5
TG - Togo 4
RU - Federazione Russa 3
BE - Belgio 2
FI - Finlandia 2
LT - Lituania 2
NL - Olanda 2
AR - Argentina 1
AT - Austria 1
DK - Danimarca 1
ES - Italia 1
ID - Indonesia 1
IS - Islanda 1
PE - Perù 1
TR - Turchia 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 634
Città #
Singapore 57
Fairfield 54
Chandler 30
Wilmington 28
Woodbridge 28
Seattle 24
Rome 23
Houston 19
Santa Clara 19
Cambridge 18
Ashburn 17
Princeton 15
San Paolo di Civitate 14
Millbury 9
Sofia 9
Lawrence 7
Andover 6
Florence 5
San Diego 5
Beijing 4
Boston 4
Dearborn 4
Lomé 4
Plano 4
Tarquinia 4
Toronto 4
Bremen 3
Bühl 3
London 3
Amsterdam 2
Bologna 2
Brussels 2
Dallas 2
Duino-Aurisina 2
New York 2
Norwalk 2
San Mateo 2
Trento 2
Trumbull 2
Ann Arbor 1
Buffalo 1
Easton 1
Federal 1
Frankfurt am Main 1
Frascati 1
Fremont 1
Guangzhou 1
Istanbul 1
Jakarta 1
Lima 1
Madrid 1
Naples 1
Newark 1
Norfolk 1
Ottawa 1
Pisa 1
Prineville 1
Reykjavik 1
Springfield 1
Stockholm 1
Tashkent 1
Vienna 1
Totale 467
Nome #
Elderly patients with PH+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment 77
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia 57
Decisional flow with a score system to start platelet-lowering treatment in patients with essential thrombocythemia (ET): Long-term results 56
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response 51
null 51
PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count 50
Mitoxantrone, Etoposide and Intermediate-dose Ara-c (mec) - An Effective Regimen For Poor Risk Acute Myeloid-leukemia 45
null 41
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment 41
null 35
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib 24
null 23
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients 20
null 19
Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront 19
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 18
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up 16
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience 14
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life 13
null 10
null 10
Totale 690
Categoria #
all - tutte 2.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.453


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202071 0 0 0 0 0 0 12 11 11 14 7 16
2020/202195 10 7 3 0 7 38 4 1 8 9 4 4
2021/2022151 2 3 13 9 29 14 0 11 11 14 25 20
2022/2023140 29 25 4 10 15 19 5 10 21 0 1 1
2023/202468 2 14 4 8 4 10 1 3 1 5 9 7
2024/2025116 3 46 13 27 20 7 0 0 0 0 0 0
Totale 690